This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendFDA EventsHeadlinesOptions ChainOwnershipTrendsBuy This Stock SVA vs. KNSA, ALVO, TARS, LQDA, FOLD, DNLI, IBRX, AGIO, IDYA, and HRMYShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include Kiniksa Pharmaceuticals International (KNSA), Alvotech (ALVO), Tarsus Pharmaceuticals (TARS), Liquidia Technologies (LQDA), Amicus Therapeutics (FOLD), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), and Harmony Biosciences (HRMY). These companies are all part of the "med - biomed/gene" industry. Sinovac Biotech vs. Its Competitors Kiniksa Pharmaceuticals International Alvotech Tarsus Pharmaceuticals Liquidia Technologies Amicus Therapeutics Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Harmony Biosciences Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Is KNSA or SVA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Sinovac Biotech's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Sinovac Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Sinovac Biotech N/A N/A N/A Which has more volatility & risk, KNSA or SVA? Kiniksa Pharmaceuticals International has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Does the media favor KNSA or SVA? In the previous week, Kiniksa Pharmaceuticals International had 6 more articles in the media than Sinovac Biotech. MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Sinovac Biotech. Kiniksa Pharmaceuticals International's average media sentiment score of 0.97 beat Sinovac Biotech's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Overall Sentiment Kiniksa Pharmaceuticals International Positive Sinovac Biotech Neutral Do analysts recommend KNSA or SVA? Kiniksa Pharmaceuticals International presently has a consensus target price of $41.17, suggesting a potential upside of 22.89%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, equities research analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, KNSA or SVA? Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M5.87-$43.19M$0.04837.50Sinovac Biotech$448.27M1.44-$99.92MN/AN/A Do institutionals & insiders hold more shares of KNSA or SVA? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryKiniksa Pharmaceuticals International beats Sinovac Biotech on 12 of the 14 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.2231.3126.60Price / Sales1.44390.30461.30121.37Price / Cash38.9544.4437.7659.36Price / Book0.058.0710.026.67Net Income-$99.92M-$54.08M$3.27B$265.59M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeKNSAKiniksa Pharmaceuticals International2.4131 of 5 stars$33.18+0.4%$41.17+24.1%+24.5%$2.46B$529.33M830.31220ALVOAlvotech2.0073 of 5 stars$8.17-1.9%$14.00+71.5%-31.5%$2.46B$491.98M35.481,032TARSTarsus Pharmaceuticals1.8228 of 5 stars$57.15+0.9%$66.67+16.7%+114.2%$2.41B$295.52M-24.5350Positive NewsLQDALiquidia Technologies3.6052 of 5 stars$26.93+2.6%$32.11+19.2%+190.2%$2.31B$14M-15.8150Positive NewsFOLDAmicus Therapeutics4.312 of 5 stars$7.50+0.2%$16.22+116.4%-33.2%$2.31B$528.29M-62.45480Positive NewsDNLIDenali Therapeutics4.2981 of 5 stars$15.58+0.0%$33.62+115.8%-37.5%$2.28B$330.53M-5.56430Positive NewsIBRXImmunityBio2.2494 of 5 stars$2.35+4.2%$10.75+358.4%-44.2%$2.21B$14.74M-4.86590News CoverageAnalyst ForecastAGIOAgios Pharmaceuticals4.3604 of 5 stars$37.40+0.4%$56.33+50.6%-16.6%$2.17B$36.50M3.40390Positive NewsIDYAIDEAYA Biosciences4.4347 of 5 stars$24.68-0.1%$48.09+94.8%-36.5%$2.16B$7M-6.5180News CoveragePositive NewsHRMYHarmony Biosciences4.6491 of 5 stars$37.31-0.3%$51.00+36.7%+6.8%$2.15B$772.53M12.04200Positive News Related Companies and Tools Related Companies KNSA Alternatives ALVO Alternatives TARS Alternatives LQDA Alternatives FOLD Alternatives DNLI Alternatives IBRX Alternatives AGIO Alternatives IDYA Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access